Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells

Anja-Kristina Brust1, Holger K Ulbrich, Gail M Seigel

  • 1Department of Ophthalmology, Johannes Gutenberg University of Mainz, Germany.

Biomarker Insights
|July 7, 2009
PubMed

Insights

Cyclooxygenase (COX)-2 inhibitors protect retinal cells from apoptosis, a key factor in glaucoma. Selective COX-2 inhibitors show significant neuroprotective effects, suggesting a novel therapeutic strategy for glaucoma.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma involves retinal ganglion cell (RGC) loss, leading to vision impairment.
  • Neuroprotection offers a strategy to prevent RGC apoptosis.
  • Cyclooxygenase (COX)-2 signaling is implicated in neuronal apoptotic death.

Purpose of the Study:

  • To investigate the neuroprotective effects of COX-1/COX-2 inhibitors on RGCs.
  • To assess the impact of these inhibitors on prostaglandin E2 (PGE2) levels.
  • To identify protein expression changes in RGCs under elevated pressure with and without COX-2 inhibition.

Main Methods:

  • Utilized the R28 neuroretinal cell line.
  • Measured PGE2 concentrations using ELISA.
  • Analyzed protein expression profiles via SELDI-TOF MS and ProteinChip analysis.

Main Results:

  • COX-2 inhibition significantly reduced RGC apoptosis and PGE2 levels.
  • Selective COX-2 inhibitors were more potent than non-selective or COX-1 inhibitors.
  • Identified differential expression of ubiquitin, HSP10, and NDKB biomarkers under elevated pressure.

Conclusions:

  • COX-2 inhibition demonstrates a clear neuroprotective effect in RGCs.
  • Selective COX-2 inhibitors present a promising therapeutic avenue for glaucoma.
  • Targeted local treatment with selective COX-2 inhibitors could be an innovative glaucoma intervention.

Related Concept Videos